AI Safety Research Neglects Post-Deployment Risks in Healthcare and Finance, SSRC Analysis of 1,178 Papers Finds

What happened

Why it matters

• ·Regulatory frameworks in healthcare and financial services increasingly require ongoing lifecycle risk management, meaning organizations that rely solely on vendor pre-deployment safety documentation may face supervisory scrutiny or compliance gaps under existing sector rules.
• ·The documented shift in research attention away from post-deployment bias and performance issues means that enterprise teams deploying AI in production cannot assume vendor safety research reflects real-world operational risks, increasing the operational burden on internal monitoring programs.
• ·The concentration of safety research at the pre-deployment stage creates organizational risk for procurement and vendor management functions, as standard vendor risk assessments and contract terms may not capture deployment-stage failure modes relevant to the organization's specific use case or user population.

Governance controls affected

What to do now

• ☐Establish an independent post-deployment monitoring program that tracks bias, hallucination rates, and performance drift against defined baseline benchmarks on a regular cadence for all AI systems operating in healthcare or financial services contexts.
• ☐Update vendor risk assessment questionnaires to include specific questions about whether the vendor's safety research covers deployment-stage scenarios, diverse user populations, and edge cases relevant to your organization's use case.
• ☐Review existing AI vendor contracts to determine whether audit rights or live operational performance benchmarks are included, and prioritize adding such provisions in renewals or new procurement agreements.
• ☐Classify AI deployments in healthcare and financial services under your risk classification framework and verify that post-deployment validation controls are formally assigned and operationally active for each high-risk system.
• ☐Brief internal compliance and risk committees on the SSRC findings to ensure that pre-deployment evaluation reports from vendors are treated as a starting point rather than a complete risk assessment when approving AI system deployments.

What to watch next

Compliance teams should monitor whether the SSRC findings prompt updated supervisory guidance or rulemaking from sector regulators in healthcare and financial services, particularly from bodies such as the FDA, ONC, CFPB, and prudential banking regulators that have already signaled interest in AI lifecycle risk management. Teams should also track whether the named developers respond publicly to the research gaps identified, as any commitments to expand post-deployment safety research could affect vendor risk profiles. Pending AI governance legislation and regulatory guidance in the European Union, the United Kingdom, and the United States may reference this type of research to justify requirements for continuous monitoring obligations beyond the point of initial deployment.